Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other equities research analysts have also commented on the company. Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $3.02 on Friday. The business’s 50-day simple moving average is $3.71 and its two-hundred day simple moving average is $8.31. The company has a market cap of $28.33 million, a PE ratio of -0.54 and a beta of 0.16. Tvardi Therapeutics has a fifty-two week low of $2.81 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors have recently modified their holdings of the business. 683 Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $4,107,000. Slate Path Capital LP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $16,427,000. Squarepoint Ops LLC lifted its position in shares of Tvardi Therapeutics by 534.3% during the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after buying an additional 43,619 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at $92,000. Finally, Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at $80,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.